Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast
Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also benefit from EGFR inhibitors (Merck & Co. / Eli Lilly’s Erbitux and Amgen’s Vectibix), which are recommended for first-line treatment of patients with left-sided tumors. Notably, additional targeted therapies for specific molecular subtypes have been developed: immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo and Yervoy) for MSI-high and/or MMR-deficient tumors; BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi) for metastatic colorectal cancer with a BRAF V600E mutation; and HER2-targeted agents in some markets (Chugai’s Perjeta and trastuzumab and Seagen’s Tukysa) for HER2-positive metastatic disease. Most therapies in late-stage development are intended to treat other genomic alterations (i.e., KRAS G12C mutation) or expand the immunotherapy-based approaches for treating MSS and/or pMMR tumors.
QUESTIONS ANSWERED
- How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers?
- What are interviewed experts’ views on current and emerging late-phase therapies, and what strategies are companies pursuing to secure uptake and share in the colorectal cancer market?
- What are the key drivers and constraints in the colorectal cancer therapy market, and how will they change over the forecast period?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENTS
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast also features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Colorectal Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Colorectal Cancer u2013 Key Findings u2013 August 2023
- Key Updates
- August 2023
- May 2023
- April 2023
- January 2023
- Q4 2022
- November 2022
- Q3 2022
- September 2022
- Market Outlook
- Key findings
- Market share of drug classes for colorectal cancer: 2022
- Market share of drug classes for colorectal cancer: 2032
- Drug-treatable population share and major-market sales share in colorectal cancer: 2022
- Drug-treatable population share and major-market sales share in colorectal cancer: 2032
- Population positioning of therapies in colorectal cancer
- Colorectal cancer SWOT analysis
- Market drivers and constraints
- What factors are driving the market for colorectal cancer?
- What factors are constraining the market for colorectal cancer?
- Major-market sales of key drug classes for colorectal cancer: 2022-2032
- Major-market sales of key drugs for colorectal cancer by brand / biosimilar: 2022-2032
- Segment-specific trends
- Patient-share dynamics of key players for stage III colon cancer in the United States: 2022-2032
- Patient-share dynamics of key players for stage IV first-line left-sided BRAF wild-type RAS wild-type colorectal cancer in the United States: 2022-2032
- Patient-share dynamics of key players for stage IV first-line right-sided BRAF wild-type RAS wild-type colorectal cancer in the United States: 2022-2032
- Patient-share dynamics of key players for stage IV first-line BRAF wild-type RAS-mutant colorectal cancer in the United States: 2022-2032
- Patient-share dynamics of key players for stage IV first-line BRAF-mutant RAS wild-type colorectal cancer in the United States: 2022-2032
- Second-line metastatic colorectal cancer
- Patient-share dynamics of key players for stage IV second-line left-sided BRAF wild-type RAS wild-type colorectal cancer in the United States: 2022-2032
- Patient-share dynamics of key players for stage IV second-line right-sided BRAF wild-type RAS wild-type colorectal cancer in the United States: 2022-2032
- Patient-share dynamics of key players for stage IV second-line BRAF wild-type RAS-mutant colorectal cancer in the United States: 2022-2032
- Patient-share dynamics of key players for stage IV second-line BRAF-mutant RAS wild-type colorectal cancer in the United States: 2022-2032
- Patient-share dynamics of key players for stage IV third- and fourth-line left-sided BRAF wild-type RAS wild-type colorectal cancer in the United States: 2022-2032
- Patient-share dynamics of key players for stage IV third- and fourth-line right-sided BRAF wild-type RAS wild-type colorectal cancer in the United States: 2022-2032
- Patient-share dynamics of key players for stage IV third- and fourth-line BRAF wild-type RAS-mutant colorectal cancer in the United States: 2022-2032
- Patient-share dynamics of key players for stage IV third- and fourth-line BRAF-mutant RAS wild-type colorectal cancer in the United States: 2022-2032
- Key findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease overview
- Disease pathophysiology
- Etiology
- Risk factors for developing colorectal cancer
- Pathophysiology
- Proposed adenoma-carcinoma sequence model for colorectal cancer with chromosomal instability
- Staging and classification
- Staging of colorectal cancer
- TNM classification of colorectal cancer
- Modified Astler-Coller Dukes staging system vs. AJCC/UICC colorectal cancer (TNM) staging system
- Symptoms according to tumor location in colorectal cancer
- Screening for colorectal cancer
- Prognostic factors in colorectal cancer
- Key pathways and drug targets
- Drug targets for colorectal cancer
- Select genes reportedly involved in colorectal cancer
- Disease overview
- Epidemiology
- Key findings
- Key updates
- Epidemiology populations
- Disease definition
- Methods
- Sources used for diagnosed incidence of colorectal cancer
- Diagnosed incident cases of colorectal cancer: 2022-2032
- Disease definition
- Methods
- Sources used for the stage distribution of colorectal cancer
- Diagnosed incident cases of colorectal cancer by stage distribution: 2022-2032
- Definition
- Methods
- Sources used for recurrent incidence of colorectal cancer
- Recurrent incident cases of colorectal cancer: 2022-2032
- Colorectal cancer patient flow
- Drug-treatable cases of colorectal cancer: 2022-2032
- Drug-treated cases of colorectal cancer: 2022-2032
- Key findings
- Current Treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for colorectal cancer
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for colorectal cancer
- Current treatments used for colorectal cancer
- Market events impacting the use of key current therapies in colorectal cancer
- Key results from select clinical trials investigating bevacizumab for the treatment of colorectal cancer
- Expert insight: bevacizumab
- Key results from select clinical trials investigating Zaltrap for the treatment of colorectal cancer
- Expert insight: Zaltrap
- Key results from select clinical trials investigating Cyramza for the treatment of colorectal cancer
- Ongoing clinical development of Cyramza
- Key ongoing clinical trials of Cyramza in the treatment of colorectal cancer
- Expert insight: Cyramza
- Key results from select clinical trials investigating Stivarga for the treatment of colorectal cancer
- Expert insight: Stivarga
- Key results from select clinical trials investigating Erbitux for the treatment of colorectal cancer
- Ongoing clinical development of Erbitux
- Expert insight: Erbitux
- Key results from select clinical trials investigating Vectibix for the treatment of colorectal cancer
- Ongoing clinical development of Vectibix
- Key ongoing clinical trials of Vectibix in the treatment of colorectal cancer
- Expert insight: Vectibix
- Key results from select clinical trials investigating Keytruda for the treatment of colorectal cancer
- Ongoing clinical development of Keytruda
- Key results from select clinical trials investigating Opdivo for the treatment of colorectal cancer
- Ongoing clinical development of Opdivo
- Key ongoing clinical trials of Opdivo in the treatment of colorectal cancer
- Expert insight: Opdivo
- Key results from select clinical trials investigating Braftovi for the treatment of colorectal cancer
- Ongoing clinical development of Braftovi
- Expert insight: Braftovi
- Key results from select clinical trials investigating Lonsurf for the treatment of colorectal cancer
- Ongoing clinical development of Lonsurf
- Expert insight: Lonsurf
- Key results from select clinical trials investigating Perjeta and trastuzumab combination therapy for the treatment of colorectal cancer
- Ongoing clinical development of Perjeta and trastuzumab combination therapy
- Expert insight: Perjeta plus trastuzumab
- Key results from select clinical trials investigating Tukysa for the treatment of colorectal cancer
- Ongoing clinical development of Tukysa
- Key ongoing clinical trials of Tukysa in the treatment of colorectal cancer
- Expert insight: Tukysa
- Medical practice
- Stage II/III colon cancer
- Stage II/III rectal cancer
- Treatment of colorectal cancer with resectable liver metastases
- Second-line treatment of metastatic colorectal cancer
- Third- and later-line treatment of metastatic colorectal cancer
- Patient characteristics influencing drug selection in colorectal cancer
- Treatment decision tree for stage II/III colon and rectal cancer: G7
- Treatment decision tree for stage IV colorectal cancer: United States
- Treatment decision tree for stage IV colorectal cancer: France, Germany, Italy, and Spain
- Treatment decision tree for stage IV colorectal cancer: United Kingdom
- Treatment decision tree for stage IV colorectal cancer: Japan
- Key findings
- Unmet Need Overview
- Current and future attainment of unmet needs in colorectal cancer
- Top unmet needs in colorectal cancer: current and future attainment
- Expert insights: unmet need in colorectal cancer
- Drug Pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for colorectal cancer
- Estimated market authorization dates of key emerging therapies for the treatment of colorectal cancer
- Key results from select clinical trials investigating fruquintinib for the treatment of colorectal cancer
- Analysis of the clinical development program for fruquintinib
- Expert insight: fruquintinib
- Expectations for market authorization and sales opportunity of fruquintinib in colorectal cancer
- Key results from select clinical trials investigating zanzalintinib for the treatment of colorectal cancer
- Analysis of the clinical development program for zanzalintinib
- Key ongoing clinical trials of zanzalintinib in the treatment of colorectal cancer
- Expert insight: zanzalintinib
- Expectations for market authorization and sales opportunity of zanzalintinib in colorectal cancer
- Key results from select clinical trials investigating Krazati for the treatment of colorectal cancer
- Analysis of the clinical development program for Krazati
- Key ongoing clinical trials of Krazati in the treatment of colorectal cancer
- Expert insight: Krazati
- Expectations for the market authorization and sales opportunity of Krazati in colorectal cancer
- Lumakras / Lumykras
- Key results from select clinical trials investigating Lumakras / Lumykras for the treatment of colorectal cancer
- Analysis of the clinical development program for Lumakras / Lumykras
- Key ongoing clinical trials of Lumakras / Lumykras in the treatment of colorectal cancer
- Expert insight: Lumakras / Lumykras
- Expectations for market authorization and sales opportunity of Lumakras / Lumykras in colorectal cancer
- Key results from select clinical trials investigating Tecentriq for the treatment of colorectal cancer
- Analysis of the clinical development program for Tecentriq
- Key ongoing clinical trials of Tecentriq in the treatment of colorectal cancer
- Expert insight: Tecentriq
- Expectations for market authorization and sales opportunity of Tecentriq in colorectal cancer
- Key results from select clinical trials investigating the favezelimab / Keytruda fixed-dose combination for the treatment of colorectal cancer
- Analysis of the clinical development program for favezelimab / Keytruda fixed-dose combination
- Key ongoing clinical trials of favezelimab / Keytruda fixed-dose combination in the treatment of colorectal cancer
- Expert insight: favezelimab / Keytruda fixed-dose combination (FDC)
- Expectations for the market authorization and sales opportunity for favezelimab / Keytruda fixed-dose combination in colorectal cancer
- Analysis of the clinical development program for Opdualag
- Key ongoing clinical trials of Opdualag in the treatment of colorectal cancer
- Expert insight: Opdualag for the treatment of colorectal cancer
- Expectations for market authorization and sales opportunity for Opdualag in colorectal cancer
- Key results from select clinical trials investigating Jemperli for the treatment of colorectal cancer
- Analysis of the clinical development program for Jemperli
- Key ongoing clinical trials of Jemperli in the treatment of colorectal cancer
- Expert insight: Jemperli
- Expectations for market authorization and sales opportunity of Jemperli in colorectal cancer
- Key results from select clinical trials investigating OncoVAX for the treatment of colorectal cancer
- Analysis of the clinical development program for OncoVAX
- Key ongoing clinical trials of OncoVAX in the treatment of colorectal cancer
- Expert insight: OncoVAX
- Expectations for market authorization and sales opportunity for OncoVAX in colorectal cancer
- Analysis of the clinical development program for futuximab/modotuximab
- Key ongoing clinical trials of futuximab/modotuximab in the treatment of colorectal cancer
- Expert insight: Sym-004
- Expectations for market authorization and sales opportunity for futuximab / modotuximab in colorectal cancer
- Early-phase pipeline analysis
- Select compounds in early-phase development for colorectal cancer
- Key findings
- Access & Reimbursement Overview
- Region-specific reimbursement practices
- Key market access considerations in colorectal cancer: United States
- General reimbursement environment: United States
- Key market access considerations in colorectal cancer: EU5
- General reimbursement environment: EU5
- Key market access considerations in colorectal cancer: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Colorectal cancer bibliography
- Abbreviations
- Key Findings
Laura Ramos Garcia, M.Sc., Ph.D., is an analyst on the Oncology team at Clarivate. During her training as a Ph.D., she gained in-depth knowledge in the field of cell death and inflammation. As a postdoctoral researcher, she worked on an emerging type of small molecule, PROTAC, that allows targeted protein degradation. She obtained her master of science degree in molecular medicine at Imperial College London and her doctorate in cancer biology at the Institute of Cancer Research (University of London).
Priyanka Sharma, M.B.A., Healthcare Research & Data Analyst, Oncology. Prior to joining this company, she was a knowledge management consultant with ZS Associates, where she was responsible for designing and conducting secondary research on disease markets and providing end-to-end support to pharmaceutical clients during products’ life cycle. She also worked at DelveInsight Business Research, where she conducted pharmaceutical market forecasting in multiple therapy areas for various clients. She holds a bachelor’s degree in pharmacy and an M.B.A. in pharmaceutical management from the University Institute of Applied Management Sciences at Panjab University in Chandigarh, India.